Donald Dvorin, MD
Allergy & Immunology · Philadelphia, PANPI 1316095664
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 671 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 24.7% of the total. Reporting peaked in 2019 at $2,286 and has fallen 99.2% since, to $19 in 2025.
Across 671 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Sanofi$650
- CSL Behring$543
- Kaleo, Inc.$437
- Novartis$426
- plus $4K from 27 others
What the payments were for
- Food & beverage$9,844100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 117 | $2,430 |
| GSK | 152 | $1,606 |
| Sanofi | 47 | $650 |
| CSL Behring | 38 | $543 |
| Kaleo, Inc. | 30 | $437 |
| Novartis | 27 | $426 |
| Optinose US, Inc. | 30 | $361 |
| Biocryst US Sales Co., LLC | 26 | $323 |
| Alk-abello, Inc | 20 | $310 |
| Boehringer Ingelheim | 19 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $260 |
| Regeneron Healthcare Solutions, Inc. | 16 | $244 |
| Philips North America LLC | 15 | $243 |
| Mylan Specialty L.p. | 15 | $206 |
| Amgen | 13 | $188 |
| Bio Products Laboratory USA, Inc. | 11 | $186 |
| Grifols USA, LLC | 8 | $145 |
| Pharming Healthcare, Inc. | 10 | $145 |
| Pfizer | 8 | $123 |
| AbbVie | 10 | $117 |
| Covis Pharma GmbH | 6 | $96 |
| Genentech USA, Inc. | 5 | $87 |
| Aimmune Therapeutics, Inc. | 6 | $87 |
| Teva Pharmaceuticals USA, Inc. | 5 | $71 |
| Hikma Pharmaceuticals USA | 4 | $62 |
| Merck | 4 | $54 |
| Blueprint Medicines Corporation | 3 | $46 |
| Eyevance Pharmaceuticals LLC | 3 | $41 |
| Shire North American Group Inc | 3 | $40 |
| Electromed, Inc. | 1 | $15 |
| LEO Pharma Inc. | 1 | $15 |
| Octapharma USA, Inc. | 1 | $13 |
| Biocryst Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,844 in reported general payments places this provider in the 70th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $108,687 |
| Dupixent SyringeDupilumab | 12 | $51,887 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $21,631 |
| Spiriva RespimatTiotropium Bromide | 14 | $19,959 |
| Arnuity ElliptaFluticasone Furoate | 41 | $17,534 |
| Qvar RedihalerBeclomethasone Dipropionate | 23 | $12,345 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 39 | $10,594 |
| Zafirlukast | 19 | $4,216 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $3,935 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $3,919 |
| Azelastine Hcl | 150 | $3,914 |
| Mometasone Furoate | 15 | $2,414 |
| Carbinoxamine Maleate | 33 | $2,121 |
| Ventolin HfaAlbuterol Sulfate | 18 | $1,850 |
| Ipratropium Bromide | 27 | $1,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,606 | $147,852159 claims |
| Boehringer IngelheimSpiriva Respimat | $261 | $19,95914 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $71 | $12,34523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Philadelphia
- Drew WeissmanPhiladelphia$12.8M
- Arnold LevinsonPhiladelphia$95K
- Elias AklPhiladelphia$80K
- Neha SirohiPhiladelphia$62K
- John BossoPhiladelphia$42K
- Marc GoldsteinPhiladelphia$22K
- Raquel EmpedradPhiladelphia$21K
- Karin Flynn-RoddenPhiladelphia$15K
- Irene HaralabatosPhiladelphia$9K
- Juen KimPhiladelphia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.